New study provides good results for Eli Lilly and Boehringer

Jardiance has shown good effect in a study of cardiovascular patients, Eli Lilly, which is developing the drug with Boehringer, reports.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly's diabetes pill Jardiance showed a 21 percent reduction in deaths and hospitalizations of adult patients with heart failure with preserved ejection fraction (HFpEF) compared to a placebo, the pharmaceutical company reported on Friday.

Jardiance is based on the active ingredient Empagliflozin and was invented by Boehringer Ingelheim, which is developing the drug in collaboration with Eli Lilly.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs